Xenon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Xenon Pharmaceuticals tiene unos fondos propios totales de $636.6M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $671.1M y $34.5M respectivamente.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$638.08m |
| Equity | US$927.92m |
| Total liabilities | US$36.88m |
| Total assets | US$964.80m |
Recent financial health updates
Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12
Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12Recent updates
Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16Financial Position Analysis
Pasivos a corto plazo: XENELos activos a corto plazo ($531.0M) de la empresa superan a sus pasivos a corto plazo ($24.7M).
Pasivo a largo plazo: XENELos activos a corto plazo ($531.0M) superan a sus pasivos a largo plazo ($9.8M).
Debt to Equity History and Analysis
Nivel de deuda: XENE está libre de deudas.
Reducción de la deuda: XENE no tiene deuda en comparación con hace 5 años, cuando su ratio deuda/fondos propios era de 13.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Cash runway estable: XENE tiene suficiente cash runway para más de 3 años basándose en su free cash flow actual.
Pronóstico de cash runway: XENE dispone de suficiente liquidez para más de 3 años si el flujo de caja libre sigue reduciéndose al ritmo histórico de 32.9% cada año